December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
2 citations
,
July 2025 in “RMD Open” IL-1 blockade is effective for treating SURF, and personalized treatment is needed.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
14 citations
,
April 2019 in “Saudi pharmaceutical journal” Microparticles help caffeic acid stay longer in hair follicles for better treatment of folliculitis.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.
August 2018 in “Online journal of neurology and brain disorders” Sodium valproate is effective in treating epilepsy, especially in patients who don't respond to other medications.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
July 2025 in “Journal of Investigative Dermatology” DACC-based dressings are more effective than silver-based ones for treating chronic wounds with antimicrobial resistance.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
8 citations
,
September 2023 in “Advanced Pharmaceutical Bulletin” Chitosan-coated spironolactone nano carriers effectively treat acne without side effects.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
50 citations
,
December 2017 in “Nanoscale” Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
30 citations
,
December 2021 in “Frontiers in Microbiology” Cepharanthine effectively reduces Herpes Simplex Virus Type 1 by blocking certain cell pathways and promoting cell death.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
3 citations
,
January 2002 in “Pediatric Drugs” Tinea capitis is a common scalp infection in children, treated with antifungal medications like griseofulvin, terbinafine, and fluconazole.
7 citations
,
January 2025 in “Journal of Medicinal Chemistry” New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
January 2025 in “Regenerative Biomaterials” The hydrogel helps reduce scarring and improve wound healing by releasing salvianolic acid B in acidic conditions.
April 2023 in “Neurology” Valproic acid is a more effective treatment for vomiting in Alexander disease than other medications, with few side effects.
3 citations
,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
15 citations
,
July 2009 in “Biomedical Chromatography” A reliable method was developed to measure aristolochic acid-I in rat blood.